Table 4 Percentage of cases with membranar immunostaining categorized in no expression, <25%, 25% a 50%, or <50% of CaV1.2 and CaV1.3 immunostaining in all analyzed regions. Membrane immunoexpression increase in hyperplastic and neoplastic lesions
No expression | (<25%) | (25% - 50%) | (>50%) | |||
|---|---|---|---|---|---|---|
M E N B R A N A R | 1.2 | Breast without alteration | 100.0% (10/10) | 0.0% (0/10) | 0.0% (0/10) | 0.0% (0/10) |
Ductal hyperplasia | 45.4% (5/11) | 36.3% (4/11) | 0.0% (0/11) | 18.1% (2/11) | ||
Ductal carcinoma in situ | 0.0% (0/5) | 40.0% (2/5) | 40.0% (2/5) | 20.0% (1/5) | ||
Invasive breast carcinoma of no special type | 0.0% (0/3) | 0.0% (0/3) | 100% (3/3) | 0.0% (0/3) | ||
1.3 | Breast without alteration | 100.0% (11/11) | 0.0% (0/11) | 0.0% (0/11) | 0.0% (0/11) | |
Ductal hyperplasia | 66.6% (8/12) | 8.3% (1/12) | 8.3% (1/12) | 16.6% (2/12) | ||
Ductal carcinoma in situ | 50.0% (3/6) | 16.6% (1/6) | 16.6% (1/6) | 16.6% (1/6) | ||
Invasive breast carcinoma of no special type | 16.6% (1/6) | 16.6% (1/6) | 33.3% (2/6) | 33.3% (2/6) |